BegoÃ±a MartÃ-n-Castillo

List of Publications by Year
in descending order

80 papers	4,593 citations	76196 40 h-index	98622 67 g-index
80 all docs	80 docs citations	80 times ranked	6961 citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin: Multi-faceted protection against cancer. Oncotarget, 2011, 2, 896-917.	0.8	263
2	Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle, 2010, 9, 1057-1064.	1.3	205
3	Metformin against TGFÎ²-induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis. Cell Cycle, 2010, 9, 4461-4468.	1.3	202
4	Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle, 2010, 9, 3831-3838.	1.3	179
5	The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment, 2011, 126, 355-364.	1.1	173
6	Autophagy positively regulates the CD44⁺CD24^{-/low}breast cancer stem-like phenotype. Cell Cycle, 2011, 10, 3871-3885.	1.3	172
7	The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle, 2013, 12, 1166-1179.	1.3	146
8	Metformin-induced preferential killing of breast cancer initiating CD44+CD24â^'/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget, 2012, 3, 395-398.	0.8	134
9	Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil. Cell Cycle, 2013, 12, 555-578.	1.3	131
10	Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle, 2012, 11, 4020-4032.	1.3	119
11	Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle, 2012, 11, 2782-2792.	1.3	116
12	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFÎ²-induced oncomiR miRNA-181a. Cell Cycle, 2011, 10, 1144-1151.	1.3	108
13	Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle, 2010, 9, 3807-14.	1.3	107
14	Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging, 2012, 4, 480-498.	1.4	104
15	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging, 2020, 12, 8-34.	1.4	99
16	The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Scientific Reports, 2013, 3, 2469.	1.6	97
17	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle, 2012, 11, 974-989.	1.3	94
18	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. Frontiers in Endocrinology, 2018, 9, 657.	1.5	85

#	Article	IF	Citations
19	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Scientific Reports, 2013, 3, 2560.	1.6	74
20	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget, 2012, 3, 1600-1614.	0.8	73
21	Metformin activates an Ataxia Telangiectasia Mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle, 2011, 10, 1499-1501.	1.3	72
22	Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. OncoImmunology, 2019, 8, e1633235.	2.1	70
23	Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer. Aging, 2011, 3, 1063-1077.	1.4	70
24	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Scientific Reports, 2013, 3, 2459.	1.6	67
25	BRCA1 and acetylâ€CoA carboxylase: The metabolic syndrome of breast cancer. Molecular Carcinogenesis, 2008, 47, 157-163.	1.3	65
26	Stem cell-like ALDH^{bright}cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle, 2013, 12, 3390-3404.	1.3	65
27	Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochemical and Biophysical Research Communications, 2010, 397, 27-33.	1.0	60
28	mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (TykerbÂ®). Clinical and Translational Oncology, 2009, 11, 455-459.	1.2	58
29	Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resistance Updates, 2011, 14, 212-223.	6.5	58
30	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging Cell, 2018, 17, e12772.	3.0	58
31	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle, 2014, 13, 1132-1144.	1.3	57
32	Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205. Cell Cycle, 2012, 11, 1235-1246.	1.3	56
33	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Scientific Reports, 2012, 2, 964.	1.6	55
34	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget, 2018, 9, 35687-35704.	0.8	55
35	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food and Chemical Toxicology, 2013, 60, 360-368.	1.8	53
36	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis, 2018, 39, 601-613.	1.3	53

#	Article	IF	Citations
37	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget, 2015, 6, 12279-12296.	0.8	53
38	Basal/HER2 breast carcinomas. Cell Cycle, 2013, 12, 225-245.	1.3	48
39	Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin). International Journal of Oncology, 2010, 37, 669-78.	1.4	46
40	Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochemical and Biophysical Research Communications, 2011, 407, 412-419.	1.0	44
41	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 1770.	1.0	42
42	Stem cell property epithelialâ€toâ€mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbituxâ„¢) efficacy in KRAS wildâ€type tumor cells. Journal of Cellular Biochemistry, 2011, 112, 10-29.	1.2	41
43	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histology and Histopathology, 2017, 32, 687-698.	0.5	40
44	Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget, 2014, 5, 2344-2348.	0.8	40
45	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging, 2020, 12, 4794-4814.	1.4	38
46	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle, 2012, 11, 865-870.	1.3	37
47	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget, 2015, 6, 32317-32338.	0.8	35
48	The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncology Reports, 2011, 25, 135-40.	1.2	34
49	If Mammalian Target of Metformin Indirectly Is Mammalian Target of Rapamycin, Then the Insulin-Like Growth Factor-1 Receptor Axis Will Audit the Efficacy of Metformin in Cancer Clinical Trials. Journal of Clinical Oncology, 2009, 27, e207-e209.	0.8	32
50	Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget, 2013, 4, 1484-1495.	0.8	31
51	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2â€driven cancer cell growth. Journal of Cellular Physiology, 2011, 226, 52-57.	2.0	28
52	Metformin and Breast Cancer: Where Are We Now?. International Journal of Molecular Sciences, 2022, 23, 2705.	1.8	26
53	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. Cell Cycle, 2015, 14, 3527-3532.	1.3	25
54	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. Aging, 2019, 11, 2874-2888.	1.4	25

#	Article	IF	Citations
55	Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. International Journal of Oncology, 2009, 35, 1369-76.	1.4	19
56	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. Cell Cycle, 2017, 16, 1022-1028.	1.3	19
57	The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. Frontiers in Oncology, 2019, 9, 193.	1.3	17
58	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers, 2020, 12, 1757.	1.7	17
59	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. Oncotarget, 2015, 6, 7104-7122.	0.8	17
60	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget, 2016, 7, 82185-82199.	0.8	16
61	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (ErbituxÃ¯Â¿Â½) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. International Journal of Oncology, 2011, 39, 1455-79.	1.4	15
62	Metformin Is a Pyridoxal-5â€²-phosphate (PLP)-Competitive Inhibitor of SHMT2. Cancers, 2021, 13, 4009.	1.7	15
63	Metformin and cancer: Quo vadis et cui bono?. Oncotarget, 2016, 7, 54096-54101.	0.8	15
64	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Carcinogenesis, 2019, 40, 27-40.	1.3	14
65	Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. Oncotarget, 2014, 5, 1942-1954.	0.8	14
66	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of Clinical Medicine, 2019, 8, 2180.	1.0	12
67	BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget, 2017, 8, 35019-35032.	0.8	12
68	Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Investigational New Drugs, 2012, 30, 846-852.	1.2	11
69	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. Oncology Reports, 2017, 38, 263-270.	1.2	11
70	Expression status of the autophagyâ€regulatory gene ATG6/BECN1 in ERBB2â€positive breast carcinomas: Bypassing ERBB2â€induced oncogenic senescence to regulate the efficacy of ERBB2â€targeted therapies. Genes Chromosomes and Cancer, 2011, 50, 284-290.	1.5	9
71	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. Oncotarget, 2017, 8, 99223-99236.	0.8	9
72	Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. Breast Cancer Research and Treatment, 2011, 126, 241-245.	1.1	6

#	Article	IF	Citations
73	Antibody microarrayâ€based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma. Journal of Surgical Oncology, 2011, 104, 106-109.	0.8	6
74	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. Oncology Reports, 2012, 27, 1887-92.	1.2	5
75	Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology. Frontiers in Oncology, 2020, 10, 620641.	1.3	5
76	Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib. Breast Cancer Research, 2011, 13, 401.	2.2	3
77	In silico clinical trials for anti-aging therapies. Aging, 2019, 11, 6591-6601.	1.4	3
78	An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients. Scientific Reports, 2015, 4, 5743.	1.6	2
79	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. Aging, 2020, 12, 21057-21075.	1.4	2
80	Metformin and breast cancer: an opportunity for pharmacogenetics. Aging, 2022, 14, 5612-5613.	1.4	1